Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
netFormulary
Home
Treatment Use
Class
Chapters
News
Reports
Contact
SEARCH
Searching for :
Adalimumab
Open monograph to display formulary status.
Formulary items found
Status
Description
Section
RED
Adalimumab Amgevita
®
(Ophthalmology)
Eye, Other anti-inflammatory preparations, 11.04.02
RED
Adalimumab Amgevita
®
(Gastroenterology)
Gastro-intestinal system, Cytokine inhibitors, 01.05.03
RED
Adalimumab Amgevita
®
(Rheumatology)
Musculoskeletal and joint diseases, Cytokine modulators, 10.01.03
RED
Adalimumab Amgevita
®
(Dermatology)
Skin, Drugs affecting the immune response, 13.05.03
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local
BNF
Section
Adalimumab
Adalimumab
Eye, Allergic And Inflammatory Eye Conditions, Inflammatory Eye Conditions, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Adalimumab
Adalimumab
Gastro-Intestinal System, Chronic Bowel Disorders, Inflammatory Bowel Disease, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Adalimumab
Adalimumab
Musculoskeletal System, Arthritis, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Adalimumab
Adalimumab
Skin, Inflammatory Skin Conditions, Eczema And Psoriasis, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Adalimumab
Adalimumab
Skin, Inflammatory Skin Conditions, Hidradenitis Suppurativa, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Links found
NICE TA 715 Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
NICE TA146: Adalimumab for the treatment of adults with psoriasis
NICE TA146: Adalimumab for the treatment of adults with psoriasis
NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40)
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199)
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375:Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis